One of the many consequences of BREXIT could be a change in the eligibility of UK researchers for participation in EU Framework programmes. It is reported that EU researchers may already be excluding UK research groups from consortia due to uncertainties about their future status. UK research partners are in 13.4% of all projects involving Irish partners in the Horizon 2020 programme, which makes them Ireland’s most popular partner country in the EU. They are closely followed by German partners, who are in 13.3% of all projects with Irish participants. This meeting will review the potential consequences of BREXIT for UK research, and the knock-on consequences for Irish researchers. Some introductory speakers will review the foreseen issues, and other interested parties from academic, business and other organisations will briefly outline their take on the issues and provide a panel discussion.

Agenda

2.30 Registration
3.00 Welcome and introduction

Speakers:

The UK researcher perspective.
Dr Mike Galsworthy. Programme Director, Scientists for EU

Potential impact of BREXIT on Irish Researchers

Panellists
Jim Codd, CIRCA Group. Consultant specialising in EU project management
Prof. Liam Gallagher, UCD – Project leader/participant in 5 current FP projects

4.30 Open Mike Session (3-minute presentations)
4.45 Q&A
5.00 Network Reception

Thanks to our sponsors

www.enterprise-ireland.com  www.rftgroup.ie

Register for this FREE event online at
www.enterprise-ireland.com/bioconnect
SPEAKER PROFILES

Mike Galsworthy is co-founder of the ‘Scientists for EU’ and ‘Healthier in the EU’ campaigns which were initiated to advocate continued EU membership during the UK’s referendum debate. He is an independent consultant in research and innovation policy and his background ranges from genetics to animal behaviour and health services research. Previous to that he worked at UCL & the Royal College of Anaesthetists. Recent work includes a series of case studies on “international innovation” by UK universities for Universities UK and an analysis of the effectiveness of EU health research programme under FP7. His commentary on UK-EU research relations has been cited in Government and House of Lords documents. Mike has analysed and written commentary (academic and lay) on EU research programmes since 2009, has given invited talks on science policy and has been vocal on why the UK should stay in the EU for science since 2013.

Jim Codd, associate director of CIRCA Group Europe, is an experienced consultant on Framework Programmes participation. He has over twenty years hands-on experience of supporting all stages of the Framework Programme research funding, including writing of applications, contract negotiations, project management and coordination. He is currently acting as financial and administrative manager to four FP7 projects and one Horizon 2020 (H2020) project and has actively supported many other FP7 and H2020 applications. He also has over twenty years of management experience in the food industry where he was responsible for driving continuous change and improvement through multifunctional teams. His responsibilities have included Quality Control, Quality Assurance, Production Management and Innovation Support.

Catriona Ward is a Senior European Advisor at Enterprise Ireland, promoting Horizon 2020 participation. She is the National Contact Point for Legal and Financial issues and for Spreading Excellence and Widening Participation. Catriona is also Ireland’s contact for the European Institute of Innovation and Technology (EIT), an EU initiative that spurs innovation and entrepreneurship across Europe. Catriona has recently acted as an independent observer for the ERA-NET cofund in renewable energy and she has managed Enterprise Ireland’s EU R&D Liaison office in Brussels throughout the Seventh Framework Programme FP7.

William Gallagher is Director of the UCD Conway Institute of Biomolecular and Biomedical Research, and Professor of Cancer Biology in the UCD School of Biomolecular & Biomedical Science. He is also the Director of the first Irish Cancer Society Collaborative Cancer Research Centre, BREAST-PREDICT. Prof Gallagher has a track record of success in attracting European funding and has participated as a co-ordinator/partner in several EU framework programmes. Previously, he co-ordinated 3 Industry-Academia Partnership (& Pathways) Programmes in breast cancer (Target-Breast), melanoma (Target-Melanoma), and prostate cancer (FAST-PATH). He currently co-ordinates the FP7 programmes, SYS-MEL, which uses systems medicine approaches to develop new diagnostic solutions in melanoma (www.sysmel.com), and RATHER, which focuses on new rationalised therapy options for difficult-to-treat breast cancer (www.rather.com). Prof. Gallagher is also co-founder and Chief Scientific Officer of OncoMark Ltd, a molecular diagnostics company focused in the oncology domain which also has a strong history of FP7-H2020 participation.